ATE512954T1 - Als inhibitoren des hepatitis-c-virus (hcv) geeignete n-phenyldioxohydropyrimidine - Google Patents

Als inhibitoren des hepatitis-c-virus (hcv) geeignete n-phenyldioxohydropyrimidine

Info

Publication number
ATE512954T1
ATE512954T1 AT08831558T AT08831558T ATE512954T1 AT E512954 T1 ATE512954 T1 AT E512954T1 AT 08831558 T AT08831558 T AT 08831558T AT 08831558 T AT08831558 T AT 08831558T AT E512954 T1 ATE512954 T1 AT E512954T1
Authority
AT
Austria
Prior art keywords
hepatitis
hcv
phenyldioxohydropyrimidines
virus
inhibitors
Prior art date
Application number
AT08831558T
Other languages
English (en)
Inventor
Pamela L Donner
John T Randolph
Allan C Krueger
David A Betebenner
Douglas K Hutchinson
Dachun Liu
Yaya Liu
Kenton L Longenecker
Clarence J Maring
John K Pratt
Todd W Rockway
Kent D Stewart
Rolf Wagner
David M Barnes
Shuang Chen
Ii Thaddeus S Franczyk
Yi Gao
Anthony R Haight
John E Hengeveld
Rodger F Henry
Brian J Kotecki
Xiaochun Lou
Geoff G Z Zhang
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE512954T1 publication Critical patent/ATE512954T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT08831558T 2007-09-17 2008-09-17 Als inhibitoren des hepatitis-c-virus (hcv) geeignete n-phenyldioxohydropyrimidine ATE512954T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97288707P 2007-09-17 2007-09-17
US9679408P 2008-09-13 2008-09-13
PCT/US2008/076594 WO2009039135A1 (en) 2007-09-17 2008-09-17 N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors

Publications (1)

Publication Number Publication Date
ATE512954T1 true ATE512954T1 (de) 2011-07-15

Family

ID=40091991

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08831558T ATE512954T1 (de) 2007-09-17 2008-09-17 Als inhibitoren des hepatitis-c-virus (hcv) geeignete n-phenyldioxohydropyrimidine

Country Status (15)

Country Link
US (2) US8178548B2 (de)
EP (3) EP2377854A1 (de)
JP (1) JP5726527B2 (de)
CN (3) CN105294569A (de)
AT (1) ATE512954T1 (de)
CA (1) CA2699989C (de)
DK (1) DK2203430T3 (de)
HK (1) HK1145839A1 (de)
HR (1) HRP20110632T1 (de)
MX (1) MX2010002904A (de)
PL (1) PL2203430T3 (de)
PT (1) PT2203430E (de)
RU (1) RU2542099C2 (de)
WO (1) WO2009039135A1 (de)
ZA (1) ZA201002690B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2377854A1 (de) 2007-09-17 2011-10-19 Abbott Laboratories Als Hepatitis-C-Hemmer verwendbare N-phenyl-dioxo-hydropyrimidine
CN101842360B (zh) 2007-09-17 2014-12-17 艾伯维巴哈马有限公司 抗感染嘧啶及其用途
KR101552474B1 (ko) * 2007-09-17 2015-09-11 애브비 바하마스 리미티드 Ｃ형 간염 치료용 우라실 또는 티민 유도체
KR20110033291A (ko) 2008-07-23 2011-03-30 에프. 호프만-라 로슈 아게 헤테로사이클릭 항바이러스 화합물
KR20110061640A (ko) 2008-09-26 2011-06-09 에프. 호프만-라 로슈 아게 Ｈｃｖ 치료용 피린 또는 피라진 유도체
MX2011004133A (es) 2008-10-30 2011-05-24 Hoffmann La Roche Derivados de arilpiridona antiviral heterociclica.
WO2010072598A1 (en) 2008-12-22 2010-07-01 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
BRPI1016266A2 (pt) 2009-03-06 2019-09-24 Hoffmann La Roche compostos antivirais heterocíclicos
RU2524573C2 (ru) * 2009-03-24 2014-07-27 Эбботт Лэборетриз Способ получения (e)-n-(3-трет-бутил-5-(2,4-диоксо-3,4-дигидропиримидин-1(2н)-ил)-2-метокси-стирил)фенил)метансульфонамида и промежуточные соединения для его получения
EP2421831A1 (de) * 2009-04-25 2012-02-29 F. Hoffmann-La Roche AG Heterocyclische antivirale verbindungen
TWI428332B (zh) 2009-06-09 2014-03-01 Hoffmann La Roche 雜環抗病毒化合物
CA2762675A1 (en) 2009-06-24 2010-12-29 F. Hoffmann-La Roche Ag Heterocyclic antiviral compound
EP2480533A1 (de) 2009-09-21 2012-08-01 F. Hoffmann-La Roche AG Heterocyclische verbindungen als viruzide
AU2010313497B2 (en) 2009-10-30 2013-08-01 Boehringer Ingelheim International Gmbh Dosage regimens for HCV combination therapy comprising BI201335, interferon alpha and ribavirin
JP2013511489A (ja) * 2009-11-21 2013-04-04 エフ．ホフマン−ラ ロシュ アーゲー 複素環式抗ウイルス化合物
AU2010333656B2 (en) * 2009-12-18 2015-08-27 Boehringer Ingelheim International Gmbh HCV combination therapy
US9216952B2 (en) 2010-03-23 2015-12-22 Abbvie Inc. Process for preparing antiviral compound
EP2590960B1 (de) * 2010-07-07 2014-06-11 F.Hoffmann-La Roche Ag Heterocyclische verbindungen als virostatika
JP5819959B2 (ja) 2010-07-16 2015-11-24 アッヴィ・バハマズ・リミテッド 抗ウイルス性化合物を調製するための方法
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
KR101774742B1 (ko) 2010-07-16 2017-09-11 애브비 아일랜드 언리미티드 컴퍼니 촉매 반응용 포스핀 리간드
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
WO2012129099A1 (en) * 2011-03-18 2012-09-27 Abbott Laboratories Formulations of phenyl uracil compounds
US8989328B2 (en) * 2013-03-14 2015-03-24 Qualcomm Incorporated Systems and methods for serial communication
US10149859B2 (en) 2013-09-11 2018-12-11 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2015197028A1 (en) * 2014-06-28 2015-12-30 Sunshine Lake Pharma Co., Ltd. Compounds as hepatitis c virus (hcv) inhibitors and uses thereof in medicine
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
JP7041140B2 (ja) 2016-11-01 2022-03-23 メルク・シャープ・アンド・ドーム・コーポレーション 置換された６員アリール又はヘテロアリール系ニコチン性アセチルコリン受容体アロステリック調節剤
CN110483496B (zh) * 2019-07-17 2021-05-04 杭州市西溪医院 一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用
EP3819006A1 (de) * 2019-11-05 2021-05-12 Technische Universität Dresden Verbindungen mit thymin-gerüst zur verwendung in der medizin
CN111018910A (zh) * 2019-12-05 2020-04-17 上海应用技术大学 一种铜催化合成含芳环α-羟基膦酸酯的方法
CN111518036A (zh) * 2020-04-29 2020-08-11 杭州勇诚睿生物科技有限公司 一种达沙布韦关键中间体的制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239888A (en) * 1974-11-04 1980-12-16 Pfizer Inc. 1-Phenyluracils
JPS60243017A (ja) * 1984-05-16 1985-12-03 Kyowa Hakko Kogyo Co Ltd 抗けいれん組成物
US5084084A (en) * 1989-07-14 1992-01-28 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
AU627906B2 (en) * 1989-07-14 1992-09-03 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
US5162326A (en) * 1990-02-15 1992-11-10 Takeda Chemical Industries, Ltd. Pyrimidinedione derivatives, their production and use
NL9001075A (de) * 1990-05-04 1991-12-02 Duphar Int Res
EP0489480A1 (de) * 1990-12-05 1992-06-10 Nissan Chemical Industries Ltd. Urazil-Derivate und diese als aktiven Bestandteil enthaltende Herbizide
JPH05213755A (ja) 1992-02-07 1993-08-24 Nikko Kyodo Co Ltd 肝臓障害治療薬
DE19528305A1 (de) 1995-08-02 1997-02-06 Bayer Ag Substituierte Phenyluracile
US6380387B1 (en) * 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
ES2282162T3 (es) 1999-12-06 2007-10-16 F. Hoffmann-La Roche Ag 4-pirimidinil-n-acil-l-fenilalanninas.
RU2264395C2 (ru) * 2000-02-04 2005-11-20 Сумитомо Кемикал Компани, Лимитед Производные урацила, гербицидная композиция, способ борьбы с сорняками и промежуточные продукты (варианты)
IL167957A (en) * 2000-02-04 2009-07-20 Sumitomo Chemical Co Hydroxypyridine compounds
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR100589964B1 (ko) * 2003-06-13 2006-06-19 주식회사 엘지생명과학 Ｃ형 간염 바이러스의 억제제
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
CN101842360B (zh) 2007-09-17 2014-12-17 艾伯维巴哈马有限公司 抗感染嘧啶及其用途
EP2377854A1 (de) 2007-09-17 2011-10-19 Abbott Laboratories Als Hepatitis-C-Hemmer verwendbare N-phenyl-dioxo-hydropyrimidine
KR101552474B1 (ko) 2007-09-17 2015-09-11 애브비 바하마스 리미티드 Ｃ형 간염 치료용 우라실 또는 티민 유도체
KR20110033291A (ko) 2008-07-23 2011-03-30 에프. 호프만-라 로슈 아게 헤테로사이클릭 항바이러스 화합물

Also Published As

Publication number Publication date
CN101918369B (zh) 2016-02-24
CN105294569A (zh) 2016-02-03
EP2203430A1 (de) 2010-07-07
EP2203430B1 (de) 2011-06-15
RU2542099C2 (ru) 2015-02-20
PL2203430T3 (pl) 2011-12-30
ZA201002690B (en) 2015-12-23
HRP20110632T1 (hr) 2011-10-31
EP2548873A1 (de) 2013-01-23
MX2010002904A (es) 2010-06-02
US8178548B2 (en) 2012-05-15
JP5726527B2 (ja) 2015-06-03
CA2699989A1 (en) 2009-03-26
DK2203430T3 (da) 2011-09-26
CN101918369A (zh) 2010-12-15
PT2203430E (pt) 2011-09-02
US20090176784A1 (en) 2009-07-09
CN105693626A (zh) 2016-06-22
EP2377854A1 (de) 2011-10-19
CA2699989C (en) 2014-03-25
RU2010114826A (ru) 2011-10-27
HK1145839A1 (en) 2011-05-06
WO2009039135A1 (en) 2009-03-26
US8986740B2 (en) 2015-03-24
US20120189580A1 (en) 2012-07-26
JP2010539188A (ja) 2010-12-16

Similar Documents

Publication Publication Date Title
ATE512954T1 (de) Als inhibitoren des hepatitis-c-virus (hcv) geeignete n-phenyldioxohydropyrimidine
MX2011009644A (es) Inhibidores del virus de la hepatitis c.
ATE546460T1 (de) Hemmer des hepatitis-c-virus
EA201001275A1 (ru) Конформационно-ограниченные бифенильные производные для применения в качестве ингибиторов вируса гепатита с
ATE547103T1 (de) Hemmer des hepatitis-c-virus
EA200970805A1 (ru) Ингибиторы серинпротеаз для лечения hcv инфекций
EA200900676A1 (ru) Ингибиторы вируса гепатита с
BR112013020042A2 (pt) inibidores de vírus da hepatite c
EA200901241A1 (ru) Соединения для лечения гепатита с
MX2013002927A (es) Inhibidores del virus de la hepatitis c.
ATE469155T1 (de) Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer
ATE483712T1 (de) Hcv-ns5b-inhibitoren
ATE551337T1 (de) Inhibitoren des hepatitis-c-virus
EA201001273A1 (ru) Ингибиторы вируса гепатита с
EA200900298A1 (ru) Ингибиторы вируса гепатита с
EA201001274A1 (ru) Имидазолилбифенильные имидазолы в качестве ингибиторов вируса гепатита с
EA201100390A1 (ru) Соединения для лечения гепатита с
NO20091845L (no) Macrocykliske peptider som hepatitt C virus-inhibitorer
ATE522532T1 (de) Verbindungen zur behandlung von hepatitis c
DK2209789T3 (da) Cyclopropyl-kondenserede indolobenzazepin HCV NS5B-hæmmere
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
ATE551343T1 (de) Tetracyclische verbindungen zur behandlung von hepatitis c
DE602008004317D1 (de) Verbindungen zur behandlung von hepatitis c
EA201170153A1 (ru) Микроциклические производные индола, пригодные в качестве ингибиторов вируса гепатита с
ATE505473T1 (de) Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2203430

Country of ref document: EP